Amdocs Limited (NASDAQ:DOX - Free Report) - Equities research analysts at Zacks Research cut their Q3 2025 earnings per share estimates for Amdocs in a research report issued to clients and investors on Wednesday, October 16th. Zacks Research analyst R. Department now expects that the technology company will post earnings of $1.59 per share for the quarter, down from their prior forecast of $1.61. The consensus estimate for Amdocs' current full-year earnings is $5.67 per share. Zacks Research also issued estimates for Amdocs' Q4 2025 earnings at $1.58 EPS, FY2025 earnings at $6.24 EPS, Q2 2026 earnings at $1.68 EPS, Q3 2026 earnings at $1.73 EPS, Q4 2026 earnings at $1.79 EPS and FY2026 earnings at $6.86 EPS.
A number of other research firms also recently commented on DOX. StockNews.com upgraded Amdocs from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 10th. Stifel Nicolaus began coverage on Amdocs in a research note on Wednesday, October 2nd. They issued a "buy" rating and a $100.00 price target for the company. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $102.00.
Get Our Latest Report on Amdocs
Amdocs Trading Up 0.1 %
Shares of Amdocs stock traded up $0.05 on Friday, hitting $90.99. 328,141 shares of the company's stock traded hands, compared to its average volume of 683,643. Amdocs has a one year low of $74.41 and a one year high of $94.04. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.24 and a quick ratio of 1.24. The stock has a market capitalization of $10.69 billion, a PE ratio of 20.45, a price-to-earnings-growth ratio of 1.42 and a beta of 0.74. The firm's 50-day moving average price is $86.42 and its two-hundred day moving average price is $83.58.
Amdocs (NASDAQ:DOX - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The technology company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.02. Amdocs had a return on equity of 17.89% and a net margin of 10.21%. The firm had revenue of $1.25 billion during the quarter, compared to analysts' expectations of $1.25 billion. During the same period in the previous year, the business posted $1.41 EPS. The company's quarterly revenue was up 1.1% compared to the same quarter last year.
Amdocs Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be given a dividend of $0.479 per share. This represents a $1.92 dividend on an annualized basis and a dividend yield of 2.11%. The ex-dividend date is Monday, September 30th. Amdocs's dividend payout ratio is currently 42.92%.
Hedge Funds Weigh In On Amdocs
Several institutional investors and hedge funds have recently modified their holdings of DOX. Raymond James & Associates lifted its stake in Amdocs by 9.5% in the third quarter. Raymond James & Associates now owns 501,104 shares of the technology company's stock valued at $43,837,000 after buying an additional 43,627 shares in the last quarter. Blue Trust Inc. lifted its position in Amdocs by 58.2% in the 3rd quarter. Blue Trust Inc. now owns 1,800 shares of the technology company's stock valued at $157,000 after acquiring an additional 662 shares in the last quarter. Net Worth Advisory Group acquired a new position in Amdocs in the 3rd quarter worth $264,000. Inspire Advisors LLC boosted its stake in Amdocs by 85.8% in the 3rd quarter. Inspire Advisors LLC now owns 11,079 shares of the technology company's stock worth $969,000 after purchasing an additional 5,117 shares during the period. Finally, Twelve Points Wealth Management LLC bought a new position in Amdocs during the 3rd quarter worth about $231,000. 92.02% of the stock is currently owned by institutional investors and hedge funds.
Amdocs Company Profile
(
Get Free Report)
Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.
Read More
Before you consider Amdocs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amdocs wasn't on the list.
While Amdocs currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.